FOOD AND DRUG ADMINISTRATION ISSUES NOTICE: ONCOLOGIC DRUGS ADVISORY COMMITTEE; NOTICE OF MEETING; ESTABLISHMENT OF A PUBLIC DOCKET; REQUEST FOR COMMENTS-NEW DRUG APPLICATION 220359, FOR CAMIZESTRANT TABLETS; SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) 218197/S-004, FOR TRUQAP (CAPIVASERTIB) TABLETS

WASHINGTON, March 9 -- Food and Drug Administration has issued a notice called: Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application 220359, for Camizestrant Tablets; Supplemental New Drug Application (sNDA) 218197/S-004, for Truqap (Capivasertib) Tablets.

The notice was published in the Federal Register on March 9 by Grace R. Graham, Deputy Commissioner for Policy, Legislation, and International Affairs.

Summary: The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulat...